CO2019011305A2 - Tratamiento de una infección vaginal bacteriana - Google Patents

Tratamiento de una infección vaginal bacteriana

Info

Publication number
CO2019011305A2
CO2019011305A2 CO2019011305A CO2019011305A CO2019011305A2 CO 2019011305 A2 CO2019011305 A2 CO 2019011305A2 CO 2019011305 A CO2019011305 A CO 2019011305A CO 2019011305 A CO2019011305 A CO 2019011305A CO 2019011305 A2 CO2019011305 A2 CO 2019011305A2
Authority
CO
Colombia
Prior art keywords
treating
vaginal infection
bacterial vaginal
bacterial
infection
Prior art date
Application number
CO2019011305A
Other languages
English (en)
Inventor
Sylwia Berdzik-Kalarus
Daniel Sulikowski
Original Assignee
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma S A filed Critical Adamed Pharma S A
Publication of CO2019011305A2 publication Critical patent/CO2019011305A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a furazidina para uso vaginal en el tratamiento de una infección vaginal bacteriana. Preferiblemente, la infección vaginal bacteriana es causada por la bacteria Gardnerella vaginalis y/o Atopobium vaginae.
CO2019011305A 2017-04-14 2019-10-11 Tratamiento de una infección vaginal bacteriana CO2019011305A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17461524.5A EP3388063A1 (en) 2017-04-14 2017-04-14 Treatment of a bacterial vaginal infection
PCT/EP2018/058508 WO2018188992A1 (en) 2017-04-14 2018-04-03 Treatment of a bacterial vaginal infection

Publications (1)

Publication Number Publication Date
CO2019011305A2 true CO2019011305A2 (es) 2019-10-31

Family

ID=58578922

Family Applications (1)

Application Number Title Priority Date Filing Date
CO2019011305A CO2019011305A2 (es) 2017-04-14 2019-10-11 Tratamiento de una infección vaginal bacteriana

Country Status (11)

Country Link
US (2) US11684608B2 (es)
EP (2) EP3388063A1 (es)
BR (1) BR112019021404A2 (es)
CO (1) CO2019011305A2 (es)
CR (1) CR20190466A (es)
EA (1) EA201992448A1 (es)
MX (1) MX2019012232A (es)
MY (1) MY196293A (es)
PH (1) PH12019502332A1 (es)
SG (1) SG11201909562PA (es)
WO (1) WO2018188992A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388063A1 (en) 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500516A (en) * 1982-10-22 1985-02-19 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr Antibacterial pharmaceutical composition
US4542020A (en) * 1984-08-17 1985-09-17 E. R. Squibb & Sons, Inc. Long-lasting adhesive antifungal suppositories
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
US20020160444A1 (en) * 2000-08-11 2002-10-31 Whitehead Institute For Biomedical Research Control of biofilm development
JP2004067599A (ja) * 2002-08-07 2004-03-04 Kunihiko Tominaga 腟内洗浄剤
WO2012106264A2 (en) * 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
EP3388063A1 (en) 2017-04-14 2018-10-17 Adamed sp. z o.o. Treatment of a bacterial vaginal infection

Also Published As

Publication number Publication date
SG11201909562PA (en) 2019-11-28
EP3388063A1 (en) 2018-10-17
CR20190466A (es) 2019-11-15
EA201992448A1 (ru) 2020-02-17
US20200078337A1 (en) 2020-03-12
EP3609493B1 (en) 2024-05-15
PH12019502332A1 (en) 2020-10-12
MX2019012232A (es) 2019-11-28
BR112019021404A2 (pt) 2020-04-28
US20230270725A1 (en) 2023-08-31
EP3609493A1 (en) 2020-02-19
WO2018188992A1 (en) 2018-10-18
MY196293A (en) 2023-03-24
US11684608B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP15018618A (es) Inhibidores no nucleósidos de la transcriptasa inversa
CL2017002176A1 (es) Identificación bacteriana y prueba de susceptibilidad antimicrobiana.
BR112018005318A2 (pt) ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
BR112015028385A2 (pt) composição compreendendo bactérias de ácido láctico para uso no tratamento preventivo e/ou curativo da vaginose bacteriana
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
ECSP12012106A (es) Terapia antiviral
CL2016001524A1 (es) Derivados antibacterianos de 1h-indazol y 1h-indol.
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
CL2020001147A1 (es) Compuestos antibacterianos
CR20110184A (es) Inhibidores de la integrasa del vih
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
BR112017014670A2 (pt) derivado de polimixina e usos do mesmo
CL2011002563A1 (es) Uso de nifuratel para tratar infecciones causadas por especies del género atopobium vaginae.
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
CO2019011305A2 (es) Tratamiento de una infección vaginal bacteriana
CL2017001245A1 (es) Metodo para tratar, prevenir o reducir el riesgo de infección cutánea
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
CL2015002759A1 (es) Métodos de tratamiento de infecciones en pacientes con sobrepeso y obesos usando antibióticos
DK3432900T3 (da) Mælkesyrebakteriesammensæting til behandling af bakterielle vaginale infektioner forårsaget af gardnerella vaginalis og, hvis de forefindes, samtidige svampeinfektioner
CL2019002203A1 (es) Nuevos compuestos heterocíclicos y sus usos en la prevención o el tratamiento de infecciones bacterianas.
EA202192716A1 (ru) Состав вагинальных таблеток
PL425327A1 (pl) Zastosowanie α,β,2',3'-tetrahydroksantohumolu
PL425328A1 (pl) Zastosowanie α,β-dihydroksantohumolu